Patented ACL Reconstruction System

Called Stratis ST ACL, the system has been cleared by the U.S. Food and Drug Administration (FDA).

The system is based on patented technology comprising reusable instruments and a fixation implant manufactured from both bioabsorbable and polymer materials. By allowing a surgeon to perform the procedure arthroscopically, both surgical time and patient trauma are reduced. The technology simplifies the surgical procedure by reducing the number of steps needed to perform the technique while also eliminating complicated, time-consuming measurements. The Stratis implant provides tissue-to-bone tunnel compression and fixation at the joint line of the femur, two key areas of need that surgeons have identified as unmet with current technology.

Stratis was developed by Scandius BioMedical, Inc. (Littleton, MA, USA), whose current focus is on arthroscopic soft tissue ACL reconstruction, with future developments addressing the areas of articular cartilage, meniscal repair, and other soft-tissue sports-related joint injuries.

"We believe Stratis will provide surgeons both surgical and clinical benefits, and we are excited to bring an innovative technology solution in an area where surgeons have expressed a need for advancement,” said Mark A. Johanson, founder, president, and CEO of Scandius BioMedical.




Related Links:
Scandius